All In Biotech

Drug Trial Radar · NCT04394351

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Sep 1, 2020

Primary completion

Jun 2, 2022

Study completion May 14, 2024

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
May 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are: * To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS) * To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE * To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation * To study the effects of dupilumab on the type 2 inflammation gene expression signature * To evaluate the concentration-time profile of functional dupilumab in serum in this population * To assess efficacy of long-term (up to 160 weeks) dupilumab treatment * To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study * To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment * To evaluate the impact of dupilumab treatment on EoE signs and symptoms

Conditions

  • Eosinophilic Esophagitis (EoE)

Interventions

  • DupilumabDrug

    Single-use, prefilled syringe

  • Matching PlaceboDrug

    Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants Achieving Peak Esophageal Intraepithelial Eosinophil Count of Less Than or Equal to (≤) 6 Eosinophils/High Power Field (Eos/Hpf) at Week 16Time frame: At Week 16

Locations

27 sites in 2 countries. Site status is shown where the registry gives one.

  • Regeneron Study Site

    Phoenix, Arizona

  • Regeneron Study Site

    Little Rock, Arkansas

  • Regeneron Study Site

    Los Angeles, California

  • Regeneron Study Site

    San Francisco, California

  • Regeneron Study Site

    Aurora, Colorado

  • Regeneron Study Site

    St. Petersburg, Florida

  • Regeneron Study Site

    Atlanta, Georgia

  • Regeneron Study Site

    Atlanta, Georgia

  • Regeneron Study Site

    Chicago, Illinois

  • Regeneron Study Site

    Indianapolis, Indiana

  • Regeneron Study Site

    Iowa City, Iowa

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Boston, Massachusetts

  • Regeneron Study Site

    Lincoln, Nebraska

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    New York, New York

  • Regeneron Study Site

    Chapel Hill, North Carolina

  • Regeneron Study Site

    Cincinnati, Ohio

  • Regeneron Study Site

    Cleveland, Ohio

  • Regeneron Study Site

    Philadelphia, Pennsylvania

  • Regeneron Study Site

    Dallas, Texas

  • Regeneron Study Site

    Fort Worth, Texas

  • Regeneron Study Site

    Houston, Texas

  • Regeneron Study Site

    Milwaukee, Wisconsin

  • Regeneron Study Site

    London, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.